Forcing price transparency in drug ads, proposing international reference pricing for Medicare Part B, and even drug importation can all be found in President Trump’s lunchbox of policy ideas to take on the drug companies, who are “getting away with murder.”
Huh, am I dreaming?
Is Donald Trump really a Republican? Is former Eli Lilly President Alex Azar, now HHS Secretary, really advocating such radical ideas, such as importation, against his pharma friends? Scott Gottlieb, our free-market fanatic FDA Commissioner is crusading against high drug prices, too: winner of Patients for Affordable Drugs Price Fighting Hero Award!
Pinch me. Am I awake?
I am awake and I’m not fooled by this subtle, probably well planned out public relations defense against the progressive and populist tide, which includes Republicans and Democrats. Forget importation this week: 92% of Republican and 96% of Democratic voters support ending the ban on Medicare negotiating drug prices. Finally, the country is united!
Ending the ban on Medicare price negotiations could bring down prices for drugs in all of Medicare.
But Alex Azar’s proposal to reduce drug prices in Medicare
is only for Part B, half the country, and on a small group of medications.
Forcing drug companies to list prices on TV drugs ads does not bring those
prices down. And the importation
idea is good, but super limited, and it’s still just talk!
Jamie Love from Knowledge Ecology International’s comment on Trump’s Medicare Part B proposal is caustic yet correct in describing the Trump administration’s policy and general approach:
“If one was to design a program that appeared to address the need to curb high prices for drugs, without doing much in Trump’s first term, and promising nothing after 2025, it might look like the proposal.”
On the other hand—and this is where compromise begins to seep in and you can’t help but know it’s because Trump is no normal Republican—the former President of Eli Lilly USA, Alex Azar, is advocating for forcing price reductions on drugs in Medicare Part B and importing foreign versions of lower-cost medications for single source drugs; and working in an administration giving voice to drug price transparency. Who would have thought that possible two years ago?
Am I dreaming?
Tagged with: Alex Azar, Donald Trump, Eli Lilly, Knowledge Ecology International, Medicare Part B, republicans, Scott Gottlieb
In the first
two weeks of January, the prospects for drug importation to help alleviate high
drug prices in the U.S. are looking good. Before summarizing recent
developments, I’ll just note that millions of Americans who can’t afford
medicines and want to save money continue to use personal drug importation,
despite the federal prohibitions. This includes physically traveling across the
border to buy from Canadian or Mexican pharmacies, through international air
travel, and ordering from international online pharmacies.
Lucia Mueller blogged about an important survey by the Campaign for Personal
Prescription Importation in which 94%
of respondents affirmed that cost is the #1 reason they rely on importation
through international online pharmacies.
Inquirer reported on Americans with Medicare falling through the
cracks on drugs dropped from formularies, particularly when they are prescribed
off-label, facing high costs and looking internationally for relief. As
reported, savings are even greater when Americans buy generic versions
overseas, of drugs that are still under patent domestically.
lot of buzz in Congress, states, and the White House on the issue of drug
importation right now. Hopefully, current laws will be amended this year to
make importation expressly permitted instead of merely tolerated.
(more…)Tagged with: Alex Azar, Daraprim, Donald Trump, Scott Gottlieb
Yesterday, with great public relations fanfare, a new report from President Trump’s HHS was released showing that drug prices in other countries are often half the price they are in America. Who would have known? Well, for starters, the millions of Americans who are forced to shop internationally in order to afford their meds. Prices in other countries are actually much less than half for many drugs, but this report only looked at drugs in Medicare Part B, ones administered in a clinical setting by a healthcare provider – not picked up at the pharmacy.
Trump’s rhetoric on drug prices is one of the few unifying issues in our deeply-divided country. Trump has stated on several occasions that the “drug companies are getting away with murder.” Murder. Now, while his administration hasn’t really done much at all on drug prices, the latest report puts it out there loud and clear: drug prices are insanely lower in other rich countries than here in the United States.
Tagged with: Alex Azar, part b, Part D, price controls, reference pricing, Stephen J. Ubl, trump